Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Sanofi, Bristol Discussing Changes To Avapro Agreement

This article was originally published in The Pink Sheet Daily

  • News
  • Lee Kalowski

Executive Summary

Sanofi and Bristol-Myers Squibb are likely to make changes to the co-promotion for the antihypertensive Avapro, Sanofi said during an Aug. 31 analysts conference call

You may also be interested in...



Size Of Bristol's Sales Force Not An Issue In Sanofi Copromotion Deal, Exec Says

Bristol-Myers Squibb's discussions with Sanofi-Aventis regarding Plavix and Avapro copromotion will focus on business needs, not relative sales force sizes, Bristol said

Size Of Bristol's Sales Force Not An Issue In Sanofi Copromotion Deal, Exec Says

Bristol-Myers Squibb's discussions with Sanofi-Aventis regarding Plavix and Avapro copromotion will focus on business needs, not relative sales force sizes, Bristol said

Sanofi-Aventis Merger Complete

Sanofi-Aventis launches as the third largest pharmaceutical company in the world following completion of the Sanofi-Synthelabo/Aventis merger

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

PS060459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By